Tuesday, October 4, 2022


Biotechnology News Magazine

Global Oral Biologics Market to Surpass US$ 11,907.2 Million by 2028, Says Coherent Market Insights

Latest Posts

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Araris Biotech Closes $24 Million Financing Round

Araris Biotech notes the proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer toward clinical development.

According to Coherent Market Insights, the global oral biologics market is estimated to be valued at US$ 1,437.4 million in 2021 and is expected to exhibit a CAGR of 35.3% over the forecast period (2021-2028).

Key Trends and Analysis of the Global Oral Biologics Market:

Key players are focused on strategies such as fund raising to boost their research and development of oral biologics for treatment of various chronic diseases such as diabetes, inflammatory bowel diseases, and others, which is expected to drive the market growth.

For instance, in December 2020, Rani Therapeutics, a clinical stage biopharmaceutical company, announced that it had raised US$ 69 Mn from Series E financing round held by BofA Securities, a financial company. The fund raised would be utilized by the Rani Therapeutics for research and development of robotic pills.

Moreover, in September 2020, Allena Pharmaceuticals, Inc. announced that it raised US$ 25 Mn from Pontifax Medison Finance, a financing company, and the fund raised would be utilized by Allena Pharmaceuticals, Inc. for research and development of product candidate reloxaliase and ALLN-346 clinical trials.

Request for Sample Pages of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/989

Furthermore, key players operating in the global oral biologics market are focusing on adoption of inorganic growth strategies such as acquisition and collaborations in order to increase their market presence in the global market. For instance, In November 2020, Novo Nordisk A/S, a pharmaceutical company announced the acquisition of Emisphere Technologies, a U.S.-based drug delivery company. The acquisition will lead to strengthen the oral biologics segment of Novo Nordisk A/S in the U.S.

Key Market Takeaways:

The global oral biologics is expected to exhibit a CAGR of 35.3% over the forecast period. This is owing to increasing merger and acquisition by key players. For instance, In May 2020, AbbVie Inc., Biopharmaceutical Company announced the acquisition of Allergan plc. Under this acquisition AbbVie acquired the various products of Allergan Plc. Pharmaceutical Company including Linzess/Constella (Linaclotide), a medication used in treatment of adults with irritable bowel syndrome with constipation (IBS‑C), and chronic idiopathic constipation (CIC).

Competitive Landscape:

Key players operating in the global oral biologics include Novo Nordisk A/S, Market Strategies, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., AbbVie Inc., Enteris BioPharma, Inc., Chiasma, Inc. and Allena Pharmaceuticals, Inc.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/989

Market Segmentation:

  • Global Oral Biologics Market, By Drug Class:
    • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
    • Hormone
    • Recombinant Enzyme
    • Guanylate Cyclase-C Agonist
    • Somatostatin Analogue
    • Others
  • Global Oral Biologics Market, By Disease Indication:
    • Diabetes
    • Hyperoxaluria
    • Acromegaly
    • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
    • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
  • Global Oral Biologics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Oral Biologics Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country
        • South Africa
        • Central Africa
        • North Africa

Related Market Intelligence Reports:

MENA Biologics & Biosimilars Market, by Product Type (Influenza Vaccines, Factor VIII, (Xyntha, Octanate, Kovaltry, Advate, Koate, Adynovate, Kogenate, Hemlibra, Elocta, Recombinate, Feiba, Immunate, Alphanate and Novoeight), Erythropoietin (Epoetin Alfa (Binocrit(2000IU and 4000IU) (Eprex (2000IU and 4000IU) Darbepoietin Alfa (Aranesp) and Epoetin Alfa-epbx (Retacrit, Recormon)), Aflibercept (EYLEA), and Ziv-Aflibercept (ZALTRAP)), by Therapeutic Application (Hemophilia, Age-related Macular Degeneration, Kidney Diseases, Influenza, and Others), and by Region/Country (Gulf and Egypt) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Read more here.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine